Perez-Ruiz F, Herrero-Beites AM, Carmona L. A two-stage approach to the treatment of hyperuricemia in gout: The "Dirty Dish" hypothesis. Arthritis Rheum. Dec 2011;63(12):4002-6.[Medline].

Markel A. Allopurinol-induced DRESS syndrome. Isr Med Assoc J. Oct 2005;7(10):656-60.[Medline].

Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum. Jan 1986;29(1):82-7. [Medline].

Vázquez-Mellado J, Morales EM, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. Oct 2001;60(10):981-3. [Medline].

Fels E, Sundy JS. Refractory gout: what is it and what to do about it?. Curr Opin Rheumatol. Mar 2008;20(2):198-202. [Medline].

Fam AG, Dunne SM, Iazzetta J, et al. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum. Jan 2001;44(1):231-8. [Medline].

Walz-LeBlanc BA, Reynolds WJ, MacFadden DK. Allopurinol sensitivity in a patient with chronic tophaceous gout: success of intravenous desensitization after failure of oral desensitization.Arthritis Rheum. Oct 1991;34(10):1329-31. [Medline].

Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. Dec 8 2005;353(23):2450-61.